RxDoctor Payments Data

Teresa Oropilla-Kiefer, MD

Psychiatry · Lexington, KYNPI 1215087036

Payments from drug & device makers

$1,557in general payments, 2019–2025

Across 75 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$243
  • Otsuka America Pharmaceutical, Inc.$219
  • Johnson & Johnson$195
  • Neurocrine Biosciences, Inc.$192
  • Alkermes, Inc.$189
  • Teva Pharmaceuticals USA, Inc.$184
  • plus $337 from 4 others

What the payments were for

  • Food & beverage$1,44693%
  • Education$1117%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,557 in reported general payments places this provider in the 70th percentile of 348 psychiatry providers in Kentucky.

See all psychiatry providers in Kentucky

Medicare billing

Part B allowed, 2024
$14,360
Medicare patients
52
Services billed
167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate26$231,603
Invega SustennaPaliperidone Palmitate31$111,902
CaplytaLumateperone Tosylate38$64,206
VraylarCariprazine Hcl33$47,152
Abilify MaintenaAripiprazole13$37,859
Lurasidone Hcl32$18,079
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl73$12,705
Clozapine62$12,186
Aripiprazole85$11,144
BelsomraSuvorexant19$8,313
DayvigoLemborexant20$6,348
Quetiapine Fumarate185$5,655
TrintellixVortioxetine Hydrobromide11$5,292
Quetiapine Fumarate ErQuetiapine Fumarate12$4,799
VyvanseLisdexamfetamine Dimesylate13$4,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$192$231,60326 claims
Johnson & JohnsonInvega Sustenna$195$111,90231 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$82$64,20638 claims
AbbVieVraylar$113$47,15233 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$219$37,85913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 348 psychiatry providers in Kentucky.

Other psychiatry in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →